Evidence map›Paper›PMID 40751559›Full record

ArticleThoracic cancer2025

The Association Between Thromboembolic Events and ALK, ROS1, RET Rearrangements or EGFR Mutations in Patients With Advanced Lung Adenocarcinoma: A Retrospective Cohort Study.

Xiaohan Qian, Mengjiao Fu, Jing Zheng, Junjun Chen, Cuihong Cai, Jianya Zhou, Jianying Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaohan QianDepartment of Respiratory Disease, Thoracic Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-4256-9321
Mengjiao FuDepartment of Respiratory Disease, Thoracic Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jing ZhengDepartment of Respiratory Disease, Thoracic Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Junjun ChenDepartment of Respiratory Disease, Thoracic Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cuihong CaiDepartment of Respiratory Disease, Thoracic Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jianya ZhouDepartment of Respiratory Disease, Thoracic Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0001-8196-0166
Jianying ZhouDepartment of Respiratory Disease, Thoracic Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-8924-935X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrevious studies have reported inconsistent findings regarding the associationbetween ALK and ROS1 rearrangements in lung cancer and thromboembolic risk. This retrospective study aimed to investigate this association in advanced lung adenocarcinoma patients with ALK, ROS1, RET rearrangements, and EGFR mutations. MATERIALS AND

methodsWe retrospectively collected information on patients with advanced lung adenocarcinoma in the First Affiliated Hospital of Zhejiang University School of Medicine from January 2013 to March 2021. All patients with confirmed ALK, ROS1, or RET rearrangements, as well as a comparison cohort of those with EGFR mutation, were included. Clinical characteristics were analyzed, and the association between driver genes and TE risks was analyzed using competing risk and logistic regression.

resultsA total of 546 patients were included in the study. Among them, those with ROS1 rearrangements exhibited the highest cumulative incidence of thromboembolic events (TEs), reaching 17.5% ± 0.2% during the peri-diagnostic period (within 6 months following diagnosis). Regardless of the entire follow-up or the peri-diagnostic period, ROS1 rearrangements were significantly associated with an increased risk of TEs. Multivariate analysis revealed ROS1 rearrangements, the number of comorbidities, the size of mediastinal lymph nodes, and elevated C-reactive protein (CRP) levels as TE risk factors during the peri-diagnostic period. Throughout the follow-up period, ROS1 rearrangements and hypertension were independent TE risk factors. In addition, the development of TE significantly affected the overall survival of patients with EGFR mutations.

conclusionROS1 rearrangements were significantly associated with an increased risk of TE.

Indexed as

Adenocarcinoma of LungAnaplastic Lymphoma KinaseGene RearrangementLung NeoplasmsMutationProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-retThromboembolismAdultAgedErbB ReceptorsFemaleHumansMaleMiddle AgedALK protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanErbB ReceptorsProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-retRET protein, humanROS1 protein, humanALKarterial thromboembolismlung adenocarcinomaRETROS1venous thromboembolism

Identifiers

PMID40751559
PMCPMC12317367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.